Tobacco Addiction: 
What do we know, and where do we go?

Charl Els, MBChB, FCPsych, MMedPsych, (cum laude), Cert. A.S.A.M., MROCC
Addiction Psychiatrist and Medical Review Officer, University of Alberta
cels@ualberta.ca

This document was peer reviewed by:
Gerald Brosky, MD, CCFP, Associate Professor,
Department of Family Medicine, Dalhousie University.
Milan Khara, MB ChB, CCFP, ASAM, Clinical Director, Tobacco
Dependence Clinic, Vancouver Coastal Health Addiction
Services, Clinical Assistant Professor,
Faculty of Medicine, University of British Columbia.
Diane Kunyk, RN, BScN, MN, Ph.D (Student), CIHR Strategic
Training Fellow, University of Alberta
Lew Piamm, BSc, MD, CCFP, Lecturer Department of Family
and Community Medicine, University of Toronto
Gaston Ostiguy, MD, MSc, FRCP(c), CSPQ Pulmonary Division,
Montreal Chest Institute, McGill University Health Centre,
Associate professor, Faculty of Medicine, McGill University.
Andrew Pipe, CM, MD, Chief, Division of Prevention and
Rehabilitation University of Ottawa Heart Institute
Peter Selby, MBBS, CCFP, MHSc, FASAM, Associate Professor,
Depts of Family and Community Medicine and Psychiatry,
University of Toronto
Richard Ward, MD, CCFP, FCFP, Clinical Associate Professor,
Faculty of Medicine, University of Calgary; Physician Lead,
Chronic Disease Management, Calgary Foothills Primary
Care Network

While these experts have screened the report for accuracy, neither they
nor their current or former organizations necessarily endorse its findings
or conclusions.

Abstract

Tobacco addiction is a chronic relapsing mental health condition, as recognized by global clinical classification systems. It is a vector-driven disease, which is prevalent, lethal, treatable, but yet undertreated. It remains the leading preventable cause of death and disease in Canada and world-wide.

Treatment is considered effective, cost-effective, and highly clinically meaningful. This paper outlines a comprehensive approach to tobacco control, and outlines the recently released Clinical Practice Guidelines, and proposes recommendations for the Canadian clinical setting. Evidence-based pharmacotherapeutic and psychosocial interventions are identified and discussed, and are considered markedly more cost-effective than most other preventive treatments or interventions.

Comprehensive approaches to tobacco control have been demonstrated to reduce morbidity and mortality, and reduce excess health expenditure. It is of fundamental importance that both clinicians and policy makers are familiar with cessation and the magnitude of the benefits of these interventions. Of equal importance are the prevention of uptake and the full integration of all principles of tobacco control in a comprehensive and contemporary strategic approach to this epidemic. It is paramount that in the 21st century that the Canadian health system develops, and delivers a state-of-the-art smoking cessation programme.

The identification and treatment of tobacco addiction is considered a standard-of-care in Canada; and all health professionals have a duty-of-care when tobacco addiction is identified.

Introduction

Tobacco addiction is a prevalent condition, affecting approximately 18% of the Canadian population costing the economy an estimated $17 billion annually and killing about 5.4 million people worldwide every year.3 Dealing with this preventable epidemic requires a comprehensive and evidence-based approach. Such an approach requires an understanding of the nature of tobacco addiction as a chronic, relapsing medical condition.3

Addiction to tobacco products is the leading preventable cause of death and disease in Canada and worldwide. But, their consumption has traditionally been viewed as a matter of personal choice, a “lifestyle decision” – not as a significant chronic relapsing, yet treatable medical condition. This narrow “de-medicalized” view of nicotine addiction as a “choice,” which can be addressed primarily through behavioral approaches, has profoundly shaped society’s response to the epidemic of tobacco-initiated disease. This perspective has regrettably precluded the
delivery of safe and effective evidence-based interventions to assist in the management of nicotine dependence. Failure to recognize the true nature of addiction as a chronic medical condition has conceivably perpetuated the epidemic, has contributed to innumerable deaths, and added significant cost to the Canadian economy.

Tobacco dependence is a bio-psycho-social condition with a multi-factorial pathogenesis, which is amenable to treatment. But, despite the accumulated evidence regarding the addictive nature of tobacco use, the systematic implementation of comprehensive evidence-based approaches to the prevention and treatment of tobacco addiction has been slow and inadequate. This paper will discuss the tobacco addiction from a medical perspective and propose a more evidence-based and comprehensive approach to the management of this ultimately lethal, yet treatable, condition.

What is addiction?

Addiction may be viewed as a chronic, relapsing brain disorder that results from the distinct effects of a specific drug on the brain, its structure and function. In addition, behaviors associated with drug consumption, and the social context in which drug-taking occurs, serves to accentuate the drug’s activity in the brain and further embed the addictive behavior. This is quickly manifested by the continued use of the drug despite the knowledge of harm, the rapid development of tolerance, the appearance of signs and symptoms of withdrawal when abstinence is attempted, and loss of control over the use of the drug. The conventional view of addiction has been described as “impaired control over a reward-seeking behavior from which harm ensues.”

Addiction, has been further defined as “repeated failures to refrain from drug use despite prior resolutions to do so,” reflecting the view that aspects of decision-making, ambivalence, and conflict, are central features of an addicted individual’s behavior and experience. Addiction refers to a syndrome, induced by exposure to a particular drug, which produces chronic changes in the brain’s “motivational system”, as a consequence of which “a reward-seeking behavior has become out of control.”

Tobacco Dependence is ‘Addiction by design’

Although the tobacco epidemic is a 20th century phenomenon, the contemporary presence of tobacco on the Canadian market is a historical anomaly. Because tobacco delivers thousands of chemicals to the user’s body with every inhalation, it can be considered a “dirty” nicotine delivery device. If tobacco products were introduced to the market for the first time today, they would be rejected as unfit for human consumption and hence it would not be a legal product. Yet tobacco continues to escape most of the governmental regulatory mechanisms developed to protect the Canadian public and its health from dangerous consumer products and medications.

Tobacco, though legal, remains the only consumer product that will kill at least one out of every two of its regular users when used exactly as intended by the manufacturer. Tobacco has been proven to have no sustenance value; it serves only to addict. Cigarettes are highly engineered drug delivery devices aimed exclusively at achieving “nicotine addiction by design”, resulting in profits for the tobacco industry and its shareholders. Over the past 50 years the tobacco industry has strenuously rejected any responsibility for the devastating health consequences of its products. It has been characteristic of the industry to consistently seek to subvert, distort, and denigrate all of the evidence that has accumulated regarding the lethal nature of its products. Its tactics are by now well known. They have frequently conspired with tobacco industry-friendly scientists and physicians with the sole aim to cast doubt on the link between smoking and the array of resulting disease states, the risks of second-hand smoke, and even on the addictive nature of nicotine. This collaboration has sabotaged public health on many occasions and continues to do so.

Tobacco addiction is a vector-driven disease

Tobacco addiction is perhaps one of the most important illnesses of our time. It remains the leading preventable cause of death and disease, and this pandemic of tobacco diseases is transmitted by an industry, which serves as its vector. The vector is maintained as a consequence of the greed of an industry unparalleled in its capacity to induce disease and suffering and unrelenting in its amoral and duplicitous conduct as it seeks to maintain billion dollar profits. David Kessler, a former Commissioner of the US Food and Drug Administration (1990-1997) aptly suggested, that, the tobacco industry ought to be dismantled. The World Health Organization’s Framework Convention on Tobacco Control urges the need for denormalization of the tobacco industry, while defining the critical need to reduce the demand for tobacco through measures of education, communication, and enhanced public awareness, and the training of health professionals so as to facilitate the effective treatment of tobacco addiction on a wide scale.

What’s in tobacco smoke, and why is it addictive?

Tobacco smoke contains over 4000 chemicals, of which there are at least 172 toxic substances, including three regulated outdoor air pollutants, 33 hazardous air pollutants, 47 chemicals restricted as hazardous waste, and 67 known human or animal carcinogens. Commenting on this unparalleled toxicity, Stan Glantz, a distinguished tobacco researcher, observed: “Each cigarette is like a little toxic waste dump on fire.”

Nicotine, although safe in pharmaceutical doses, is considered the fundamental ‘driver’ of the process of addiction in the brain. Cigarettes without nicotine are not addictive. Repeated exposure to nicotine from tobacco smoke leads to complex neurophysiological transformations, resulting in disordered brain structure and function. Following inhalation, nicotine is rapidly
delivered in the arterial system to the brain where it binds primarily to alpha-4 beta-2 (α4β2) nicotinic receptors, structures central to the initiation and maintenance of the addictive state. These receptors are a natural ligand for acetylcholine. When chronically stimulated by nicotine, upregulation and desensitization of these receptors follow. Stimulation of these nicotinic receptors causes the generation of an action potential whose transmission stimulates other brain centers, resulting in the release of dopamine in the “pleasure center” of the brain. The reward pathway also becomes desensitized as a result of chronic exposure to the drug nicotine, and represents a second major maladaptive change in brain function that follows tobacco administration. It is further suggested that 40-60% of the syndrome of tobacco addiction is genetically modulated.

These changes in a smoker’s brain are the neurological underpinnings of the syndrome of tobacco addiction, or nicotine dependence, a syndrome carefully described in global clinical classification systems like the ICD-10 and the DSM IV-TR, and recognized as a chronic, relapsing medical condition by countless health authorities, including Health Canada, the Canadian Medical Association, and the World Health Organization. An overwhelming body of clinical and scientific evidence supports the view that tobacco use, far from being a “bad habit” or a “lifestyle choice,” is a pervasive and persistent addictive condition. This addiction is perpetuated by the ability of cigarettes, in reality sophisticated drug delivery devices, to rapidly introduce nicotine and a host of other chemicals to the addiction centers of the brain. The prevalence of this addiction in our communities, and the burdens of the disease imposed on society, poses significant challenges to health professionals, policy makers, and governments. It is clear that there is an urgent need for a comprehensive national response to this modern pandemic.

Treatment for tobacco addiction does work

It is hopelessly outdated to suggest: “willpower alone is enough to quit”. Such a view betrays a pronounced misunderstanding of the mechanisms inducing and maintaining addiction. Quitting “cold turkey” does not generally translate into sustained abstinence from tobacco, and results in unnecessarily low rates of success for most smokers. It is also important to recognize that today’s smokers may be more addicted than many of their predecessors for whom cessation may have been relatively easier. In an age of smoking restrictions and the growing denormalization of tobacco use, those who continue to smoke are likely those for whom cessation is much more difficult. These individuals may have genomic predispositions which make the task of cessation much harder; a topic beyond discussion in this document. Only 3%–5% of smokers who try to quit without treatment achieve prolonged abstinence for 6-12 months after a given quit attempt, with most relapsing within the first 8 days of attempting to quit. More reports of relapse curves of self-quitters are needed, and cessation studies should also report relapse curves. The low spontaneous quit rates are in stark contrast to the significantly higher likelihood of sustained abstinence when individuals receive multimodal treatment for their addiction in accordance to internationally promulgated clinical guidelines.

Smoking cessation is considered the ‘gold standard’ of preventive clinical interventions. Only nine smokers need to be successfully assisted with cessation in order to prevent one premature tobacco-related death. No other preventive interventions are as robust; many of the classical preventive strategies, e.g. control of hypertension, treatment of dyslipidemia require the treatment of vastly more patients to show a similar effect. Evidence-based treatments of nicotine addiction are considered safe, effective and remarkably cost-effective.

Cessation is a pivotal opportunity for health promotion

Despite the existence of internationally recognized treatment guidelines, an array of highly effective therapies, and the recognition of the need for concerted attempts to assist smokers, this addiction remains largely untreated. This represents one of the most significant missed opportunities in public health. It is perhaps best explained as reflecting outdated concepts regarding the underlying mechanism, which perpetuates smoking and is in part a legacy of the tobacco industries’ lavish and longstanding efforts to portray smoking purely as a matter of individual choice.

There are abundant opportunities for us to dramatically improve the health of Canadians. As our population ages, and as the burden of chronic disease (many caused or accentuated by tobacco addiction) increases in our communities, the argument for the development of new strategies becomes all the more compelling. It is important to ensure the availability, affordability, and accessibility of integrated behavioural and pharmacological treatment in every community. Cessation interventions must be delivered, as part of standard care, in every health institution and setting. Provision of pharmacotherapy for cessation must be standard practice in every jurisdiction. The screening for tobacco addiction and the provision of cessation treatment must be seen as part of a duty-of-care and a standard-of-practice for every health professional, as is the case with other medical conditions.

What is a rational approach to the treatment?

As addiction is a chronic condition, the use of a short-term, acute care paradigm for the treatment of a chronic condition like tobacco addiction is illogical and compromises the chances of cessation success. Such practices are themselves an unfortunate legacy of the “just be strong” perspective that guided cessation attempts in the past and which maintained that a “little bit of help is all you should need” given that “moral fiber” was seen as the ultimate determinant of cessation success. Fortunately, contemporary best practices reflect a far more realistic understanding of the nature of tobacco addiction and the processes required
to successfully combat it. A short-term focus on “curing” an addictive disorder will be unsuccessful in a large number of cases. The most rational approach to the management of this disorder is reflected in a dovetailing of behavioural and pharmaceutical cessation interventions. Such strategies can be developed and implemented in a highly time-efficient manner and have demonstrated clinical effectiveness, and the details are described below.

**Recommendations**

For primary care physicians and other health professionals, the current evidence-based guidelines suggest: consistent screening for, and documentation of, tobacco use; the provision of specific advice regarding the benefits of cessation; an offer of particular assistance with a cessation attempt; and arrangements for appropriate follow-up. This “5-A Approach” is considered standard: Ask, Advise, Assess, Assist, and Arrange follow-up. The consistent application of such a strategy is consistent with a longitudinal approach to the management of this chronic disease. Clinical evidence supports the offer, and provision, of safe and effective treatment to every person addicted to tobacco. A combination of simple, strategic behavioural counseling and pharmacotherapy should be offered to every smoker interested in quitting – and will dramatically enhance the likelihood of a successful quit attempt. Those who are not ready to make an attempt at cessation should be offered simple, sympathetic counseling designed to permit a reassessment of their reasons for continued smoking and an invitation to seek assistance with cessation at any time.

Several levels of evidence support the use of the following modalities:

**A. Pharmacological interventions**

**Nicotine replacement therapy (NRT)** is available in four forms (transdermal patch, chewing ‘gum’, inhaler/vaporizer, and lozenge). All smokers seek to maintain a certain, individualized level of nicotine; and when nicotine levels fall, distinct and usually significant discomfort occurs (withdrawal symptoms) serving to overturn any conscious decisions to stop smoking. The provision of nicotine (delivered via the venous system following its administration to the skin or mucous membranes of the mouth and throat) stimulates nicotine receptors and extinguishes the symptoms of withdrawal permitting a would-be non-smoker to go about normal activities free of the discomfort that normally occurs with cessation attempts. The appropriate use of NRT (particularly when titrated to reflect a person’s individual need for a certain level of nicotine) is efficacious and usually doubles success rates. Combinations of NRT (i.e. use of the patch and the inhaler) are associated with increased levels of success. The scientific evidence does not support the use of alternative tobacco-based nicotine delivery systems, e.g. smokeless tobacco, or ‘snus’ as an aid to smoking cessation. Despite claims to the contrary, these are not considered to serve as a “harm reduction” measure, and may discourage or postpone cessation efforts in smokers who would otherwise have quit, or may induce another form of tobacco dependency with associated health consequences, e.g. pancreatic cancer.

**Bupropion** is a medication initially used as an anti-depressant; it was subsequently, and serendipitously, found to be effective in producing cessation. However, its mechanism of action for smoking cessation is largely unknown. It is now understood that bupropion maintains levels of dopamine in the reward centers of the brain while affecting levels of norpinephrine, a chemical known to be associated with the development of the symptoms of withdrawal. Its use has been shown to double the success rates in those attempting to quit smoking.

**Varenicline**, a third-generation smoking cessation pharmacotherapy, directly and distinctly binds to the α4β2 nicotinic receptors (the brain receptors normally stimulated by nicotine). The receptor sites are completely blocked (in exactly the same way that a key in a lock prevents the insertion of another key) but are only partially stimulated. Thus, there is a transmitted neurological impulse that, while reduced in intensity, still causes the release of dopamine, in reduced amounts, in the reward centers of the brain. As a result, the smoker experiences little to no withdrawal symptoms and if a cigarette is smoked, no pleasurable sensation is experienced (the ‘key in the lock’ prevents the nicotine ‘key’ from being inserted). Varenicline has been shown to be the most superior pharmacotherapy for cessation when compared with NRT and bupropion. The odds ratio of quitting with varenicline is approximately 3:1, and current evidence suggests that it is not associated with a higher rate of neuropsychiatric adverse effects than placebo or bupropion, with the exception of the symptom of insomnia. 

**B. Psychosocial interventions**, or counseling (group or individual; office-based, telephone, or web-based) should be routinely offered in combination with medication in order to yield enhanced success in cessation outcomes. The provision of simple, strategic advice regarding the avoidance of high-risk situations for relapse, the recognition of settings or circumstances in which smoking has been particularly common; the management of acute cravings, and the development of family smoking guidelines for home and car are all important in accentuating the likelihood of cessation success.

Although the evidence suggests that interventions are effective across a broad range of populations, tailored interventions may be advised for selected sub-populations,
Towards Canadian Guidelines for Tobacco Addiction Treatment

At the 58th Annual Meeting of the Canadian Psychiatric Association, the Addiction Section of the CPA adopted the USDHHS Clinical Practice Guidelines as a template for the guidance of their members as they deliver smoking cessation treatments to their patients and communities. Members of the Section reviewed the USDHHS Guidelines and noted:

1. “It is essential that clinicians and healthcare delivery systems consistently identify and document tobacco use status and treat every tobacco user seen in a healthcare setting.

2. Tobacco dependence (TD) is a chronic disease that often requires repeated intervention and multiple attempts to quit. Effective treatments exist, however, that can significantly increase rates of long-term abstinence.

3. Tobacco Dependence treatment (TDRx) is effective across a broad range of populations. Clinicians should encourage every patient willing to make a quit attempt to use the counseling treatments and medications recommended in this Guideline (see #6).

4. Brief TDRx is effective. Clinicians should offer every patient who uses tobacco at least the brief treatments shown to be effective in this section.

5. Individual, group, and telephone counseling are effective, and their effectiveness increases with treatment intensity. Two components of counseling are especially effective, and clinicians should use these when counseling patients making a quit attempt: Practical counseling (problem solving/skills training), social support delivered as part of treatment.

6. Effective medications are available for TD, and clinicians should encourage their use by all patients attempting to quit smoking – except when medically contraindicated or with specific populations for which there is insufficient evidence of effectiveness (i.e., pregnant women, smokeless tobacco users, light smokers, and adolescents). Six (in Canada) first-line medications reliably increase sustained abstinence.

7. Counseling and medication are effective when used by themselves for treating TD. The combination of counseling and medication, however, is more effective than either alone. Thus, clinicians should encourage all individuals making a quit attempt to use both counseling and medication.

8. Telephone quitline counseling is effective with diverse populations and has broad reach. Therefore, both clinicians and healthcare delivery systems should ensure patient access to quitlines and promote quitline use.

9. If a tobacco user currently is unwilling to make a quit attempt, clinicians should use motivational treatments in increasing future quit attempts.

10. TDRx is both clinically effective and highly cost-effective relative to interventions for other clinical disorders. Providing coverage for these treatments increases quit rates. Insurers and purchasers should ensure that all insurance plans include the counseling and medication identified as effective as covered benefits.”

e.g. incarcerated individuals, the mentally ill, pregnant smokers, smokeless tobacco users, and those belonging to minority ethnic groups. Persons with mental illness and chemical dependence also predominantly die of tobacco-related illnesses, and have been shown to also be interested and able to quit smoking when offered appropriate interventions.

Optimal tobacco control programs require an array of integrated strategies and interventions. Appropriate levels of taxation will have a significant impact on deterring smoking (particularly among adolescents) while reinforcing commitments to cessation. Legislation to protect against exposure to second-hand smoke serves to minimize the significant risks of exposure, denormalize smoking, induces quit attempts, and reinforces the commitment to cessation.

Conclusions

Tobacco addiction is a vector-driven chronic disease, which is prevalent, lethal, treatable, but yet undertreated. The development of comprehensive approaches to tobacco control will save lives and dollars. It is of fundamental importance that policy makers are made aware that assistance with cessation will be more effective and more cost efficient than programmes designed to ensure that smoking is never commenced – both are obviously important, but the magnitude of the health and economic benefits of cessation programmes delivered to the current cohort of smokers make the former strategy an important, and heretofore largely neglected, element of a contemporary approach to the tobacco disease epidemic.

It is paramount that in the 21st century that the Canadian health system develops, and delivers a state-of-the-art smoking cessation programme. At a time of heightened economic pressure, such an approach will produce significant savings in reduced re-admissions, recurrences of illness, and progression of disease than any other preventive intervention. Such interventions are markedly cheaper than virtually all other preventive treatments or intercessions. It is no longer acceptable to use outdated techniques, or to permit anti-
quated attitudes that preclude the development and implementation of best practice solutions to the management of this leading cause of preventable disease, disability, and premature death in Canada. The identification and treatment of tobacco addiction is now seen as a standard-of-care in Canada; more importantly there is an emerging consensus that all health professionals have a duty-of-care when tobacco addiction is identified.

References:

Figure 1: Patient Reminders

Canadian Online Resources

CAN-ADAPTT
www.can-adaptt.net

Canadian Cancer Society
www.cancer.ca

Canadian Council for Tobacco Control
www.cctc.ca

Canadian Lung Association
www.lung.ca

Canada On-line
www.canaonline.about.com/od/quitsmoking/

Health Canada
www.gosmokefree.ca

Heart & Stroke Foundation
www.heartandstroke.ca

Physicians for a Smoke-Free Canada
www.smoke-free.ca

Training Enhancement in Applied Cessation Counselling and Health (TEACH)
www.teachproject.ca

Treat Tobacco Use and Dependence: 2008 Update – Clinical Practice Guideline
www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf

Telephone Support

Smoker’s Helplines
www.smokershelplineworks.ca

This publication is made possible by an unrestricted educational grant from Pfizer Canada Inc.

©2009 Published by SNELL Medical Communication Inc. through an unrestricted educational grant from Pfizer Canada Inc. All rights reserved. The opinions expressed in this publication do not necessarily reflect those of the publisher or its educational sponsor, but rather are those of the authors based on the available scientific literature. The administration of any therapies discussed or referred to should always be consistent with the recognized prescribing information as required in Canada. SNELL Medical Communication Inc. is committed to the development of superior Continuing Medical Education.